FOSUN PHARMA announced that the drug registration application for Taohong Siwu Tang Granules, a Traditional Chinese Medicine Class 3.1 new drug, has been accepted by the National Medical Products Administration. The application was submitted by the company's controlled subsidiary, Hebei Wanbang Fulin Pharmaceutical Co., Ltd. This drug is indicated for nourishing blood, activating blood circulation, and dispelling blood stasis, intended for the treatment of blood deficiency and blood stasis syndrome, with symptoms such as irregular menstruation, heavy menstrual flow with clots, purple and sticky menstrual quality, abdominal pain, and bloating. The prescription originates from the Taohong Siwu Tang formula recorded in the Qing Dynasty medical text "Fuke Bingjian" and is included in the National Administration of Traditional Chinese Medicine's "Catalogue of Ancient Classical Famous Formulas (First Batch)". As of April 2026, the cumulative R&D investment by the Group for this drug amounts to approximately RMB 6.96 million (unaudited). As of the date of this announcement, only two Taohong Siwu Tang Granules products have been approved for marketing in mainland China, with approval dates in April 2025 and April 2026, respectively. Currently, sales data for these products in mainland China for the year 2025 is not yet available in the IQVIA CHPA database.